Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:2224
Name essential thrombocythemia
Definition A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results_in the overproduction of platelets.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myeloproliferative neoplasm essential thrombocythemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 V617F BMS-911543 essential thrombocythemia sensitive detail...
TP53 mutant N/A essential thrombocythemia not applicable detail...
IDH2 mutant N/A essential thrombocythemia not applicable detail...
JAK2 V617F INCB053914 essential thrombocythemia predicted - sensitive detail...
JAK2 mutant N/A essential thrombocythemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0
NCT03123588 Phase II Ruxolitinib Anagrelide Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) Terminated USA 0
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 7
NCT04262141 Phase II IMG-7289 IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Recruiting USA 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04644211 Phase II Ruxolitinib Ruxolitinib in Thrombocythemia and Polycythemia Vera Recruiting USA 0
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting USA 0
NCT05936359 Phase I INCA033989 INCA033989 + Ruxolitinib A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER) Recruiting ITA | GBR | FRA | ESP | DEU | CAN | AUS 2
NCT06034002 Phase I INCA033989 A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms (LIMBER) Recruiting USA 0
NCT06150157 Phase I JNJ-88549968 A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms Recruiting USA | FRA | ESP | CAN 0
NCT06218628 Phase I Pacritinib + Talazoparib Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Recruiting USA 0
NCT06291987 Phase I Ivosidenib + Ruxolitinib Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs (MPN) Not yet recruiting USA 0
NCT06343805 Phase I AJ1-11095 A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) Not yet recruiting USA 0